Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

Hepatic VOD has been reported in pts with AML exposed to the CD33-directed antibody-drug conjugate GO prior to SCT. To determine VOD risk and outcomes after GO exposure and subsequent SCT, we analyzed data from a subset of pts randomly selected for research level reporting to the Center for International Blood & Marrow Transplant Research (CIBMTR). Adults with AML and GO exposure before first myeloablative allogeneic SCT were matched 1:4 by age...